Dan-Ni Ren
Overview
Explore the profile of Dan-Ni Ren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Chen J, Wo D, Ma E, Yan H, Peng J, et al.
FEBS J
. 2025 Mar;
PMID: 40022442
C-X-C chemokine receptor type 4 (CXCR4) belongs to the seven-span G protein-coupled receptor family and plays an important role in promoting cancer metastasis. The single-span receptor, low-density lipoprotein receptor-related protein...
2.
Ge Y, Ma E, Guo X, Wang Q, Zhu W, Ren D, et al.
J Cell Mol Med
. 2025 Feb;
29(4):e70388.
PMID: 39988987
Heart failure (HF) remains the leading cause of mortality worldwide. Although various drugs are currently used in the treatment of HF, including angiotensin receptor blockers, angiotensin-converting enzyme inhibitors and beta...
3.
Zhu X, Ma E, Ge Y, Yuan M, Guo X, Peng J, et al.
Biomed Pharmacother
. 2024 Mar;
174:116476.
PMID: 38520872
Background: Increasing global overweight and obesity rates not only increase the prevalence of myocardial infarction (MI), but also exacerbate ischemic injury and result in worsened prognosis. Currently, there are no...
4.
Ma E, Wo D, Chen J, Yan H, Zhou X, He J, et al.
Eur Heart J
. 2023 Dec;
45(9):688-703.
PMID: 38152853
Background And Aims: Anti-hypertensive agents are one of the most frequently used drugs worldwide. However, no blood pressure-lowering strategy is superior to placebo with respect to survival in diabetic hypertensive...
5.
Ning Y, Yuan Z, Wang Q, He J, Zhu W, Ren D, et al.
Phytother Res
. 2023 Dec;
38(2):1013-1027.
PMID: 38140774
Type 2 diabetes (T2D) is a metabolic disorder that causes numerous complications including impaired wound healing and poses a significant challenge for the management of diabetic patients. Epigallocatechin-3-gallate (EGCG) is...
6.
Ma E, Wu C, Chen J, Wo D, Ren D, Yan H, et al.
Biomed Pharmacother
. 2023 Aug;
165:115275.
PMID: 37541173
Background: Pathological cardiac hypertrophy is a hallmark of various cardiovascular diseases (CVD) including chronic heart failure (HF) and an important target for the treatment of these diseases. Aberrant activation of...
7.
Qiu Z, Wo D, Zhong X, Chen J, Ma E, He J, et al.
Integr Cancer Ther
. 2023 Apr;
22:15347354231168369.
PMID: 37077153
Background: Cancer cachexia is a common but severe condition that causes muscle wasting, body weight loss, and progressive functional impairment, affecting over 50% of cancer patients. Currently, there are no...
8.
Shen F, Wu C, Zhong X, Ma E, Peng J, Zhu W, et al.
Biomed Pharmacother
. 2023 Apr;
162:114675.
PMID: 37044026
Background: Myocardial infarction (MI) is the leading cause of deaths worldwide, triggering widespread and irreversible damage to the heart. Currently, there are no drugs that can reverse ischemic damage to...
9.
Gao Q, Ma E, Chen J, Zhao Q, He J, Peng J, et al.
Heliyon
. 2022 Dec;
8(12):e12099.
PMID: 36578425
Obesity rates have rapidly increased worldwide and obesity-related diseases such as hypertension and cardiovascular diseases have become leading factors for global morbidity and mortality. Currently, there are no effective treatments...
10.
He J, Wo D, Ma E, Wang Q, Chen J, Gao Q, et al.
Phytomedicine
. 2022 Jul;
104:154293.
PMID: 35785558
Background: Myocardial infarction (MI) is the most common cause of cardiac injury, resulting in widespread and irreversible damage to the heart. The incidence of MI gives rise to the excessive...